(Q22241427)

Dimensions Publication ID

Dimensions

1045196362

The Effect of Family Interventions on Relapse and Rehospitalization in Schizophrenia--A Meta-analysis

6 February 2023

language of work or name

English

0 references

publication date

September 2009

0 references

published in

CNS Drugs

0 references

volume

23

0 references

issue

Supplement 1

0 references

page(s)

21-31

0 references

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00023210-200923000-00004

Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data

21 January 2018

1 reference

12 December 2020

Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness

1 reference

12 December 2020

Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Reliability and validity of the SKAMP rating scale in a laboratory school setting

1 reference

12 December 2020

Attention-deficit hyperactivity disorder

1 reference

12 December 2020

A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder.

1 reference

12 December 2020

Which treatment for whom for ADHD? Moderators of treatment response in the MTA.

1 reference

12 December 2020

Long-term effects of extended-release mixed amphetamine salts treatment of attention- deficit/hyperactivity disorder on growth

1 reference

12 December 2020

Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study

1 reference

12 December 2020

Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment Study of children with ADHD (MTA): Part II: supporting details

1 reference

12 December 2020

Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium.

1 reference

12 December 2020

Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): part I: executive summary

1 reference

12 December 2020

Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Generalised anxiety disorder

1 reference

12 December 2020

A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD.

1 reference

12 December 2020

Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with Attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome

1 reference

12 December 2020

A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD

1 reference

12 December 2020

The laboratory school protocol: its origin, use, and new applications.

1 reference

12 December 2020

Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders?

1 reference

12 December 2020

Defining the boundaries of childhood bipolar disorder.

1 reference

12 December 2020

Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD

1 reference

12 December 2020

Non-stimulant medications in the treatment of ADHD.

1 reference

12 December 2020

Effects of Stimulant Medication on Growth Rates Across 3 Years in the MTA Follow-up

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder

1 reference

12 December 2020

Pharmacotherapy of attention-deficit/hyperactivity disorder: nonstimulant medication approaches.

1 reference

12 December 2020

Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle

1 reference

12 December 2020

Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine

1 reference

12 December 2020

3-Year Follow-up of the NIMH MTA Study

1 reference

12 December 2020

Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity

1 reference

12 December 2020

Treatment of hyperactivity in children with pervasive developmental disorders

1 reference

12 December 2020

Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.

1 reference

12 December 2020

Unravelling sleep problems in treated and untreated children with ADHD.

1 reference

12 December 2020

1 reference

12 December 2020

Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetine.

1 reference

12 December 2020

Treatment of attention deficit hyperactivity disorder in children

1 reference

12 December 2020

Efficacy and safety of modafinil film-coated tablets in children and adolescents with or without prior stimulant treatment for attention-deficit/hyperactivity disorder: pooled analysis of 3 randomized, double-blind, placebo-controlled studies.

1 reference

12 December 2020

Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD.

1 reference

12 December 2020

A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder

1 reference

12 December 2020

Do individuals with ADHD self-medicate with cigarettes and substances of abuse? Results from a controlled family study of ADHD.

1 reference

12 December 2020

The worldwide prevalence of ADHD: is it an American condition?

1 reference

12 December 2020

Advances in the Pharmacotherapy of Attention‐Deficit‐Hyperactivity Disorder: Focus on Methylphenidate Formulations

1 reference

12 December 2020

Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.

1 reference

12 December 2020

Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study

1 reference

12 December 2020

Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Attention-deficit/hyperactivity disorder in pediatric patients with epilepsy: review of pharmacological treatment

1 reference

12 December 2020

The pharmacogenomic era: promise for personalizing attention deficit hyperactivity disorder therapy

1 reference

12 December 2020

Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression.

1 reference

12 December 2020

Effect of stimulants on height and weight: a review of the literature

1 reference

12 December 2020

Review of long-acting stimulants in the treatment of attention deficit hyperactivity disorder

1 reference

12 December 2020

Innovations in attention-deficit/hyperactivity disorder pharmacotherapy: long-acting stimulant and nonstimulant treatments

1 reference

12 December 2020

An expert opinion on methylphenidate treatment for attention deficit hyperactivity disorder in pediatric patients with epilepsy

1 reference

12 December 2020

ADHD and substance use disorders: developmental aspects and the impact of stimulant treatment

1 reference

12 December 2020

Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes

1 reference

12 December 2020

Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression

1 reference

12 December 2020

A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder

1 reference

12 December 2020

A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).

1 reference

12 December 2020

Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction

1 reference

12 December 2020

The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications.

1 reference

12 December 2020

Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study

1 reference

12 December 2020